JAZZ News and Press, Jazz Pharmaceuticals plc From 08/12/19

Jazz Pharmaceuticals (NASDAQ: JAZZ ) has acquired privately held clinical-stage biotech Cavion for up to $312.5M, consisting of $52.5M upfront and up to $260.0M in milestones. More news on: Jazz Pharmaceuticals plc, Healthcare stocks news, Merger & acquisition news, Read more ....

Transaction Adds Worldwide Rights to CX-8998, a Modulator of T-type Calcium Channels, for the Potential Treatment of Essential Tremor Strong Strategic Fit with a Differentiated Mechanism of Action in an Area of High Unmet Need and Limited Treatment Options Represents Attractive Op...

Jazz Pharmaceuticals plc (JAZZ) Q2 2019 Results Earnings Conference Call August 06, 2019, 04:30 PM ET Company Participants Katherine Littrell - Vice President, Investor Relations Bruce Cozadd - Chairman and Chief Executive Officer Rob Iannone - Executive Vice President, R&D ...

Jazz Pharmaceuticals (NASDAQ: JAZZ ) Q2 results : More news on: Jazz Pharmaceuticals plc, Healthcare stocks news, Earnings news and commentary, Stocks on the move, Read more ...

The following slide deck was published by Jazz Pharmaceuticals plc in conjunction with their 2019 Q2 earnings Read more ...

Jazz Pharmaceuticals (NASDAQ: JAZZ ): Q2 Non-GAAP EPS of $4.05 beats by $0.48 ; GAAP EPS of $4.45 beats by $3.73 . Revenue of $534.13M (+6.7% Y/Y) beats by $26.9M . Shares +0.5% . Press Release More news on: Jazz Pharmaceuticals plc, Earnings news and commentary, Healthcare sto...

Jazz Pharmaceuticals (NASDAQ: JAZZ ) is scheduled to announce Q2 earnings results on Tuesday, August 6th, after market close. The consensus EPS Estimate is $3.57 (+2.3% Y/Y) and the consensus Revenue Estimate is $507.23M (+1.4% Y/Y). Over the last 2 years, jazz has beaten EPS estimate...

DUBLIN , July 23, 2019 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2019 second quarter financial results on Tuesday, August 6, 2019 , after the close of the financial markets.  Company management will host a live audio webcast imme...

Jazz Pharmaceuticals ( JAZZ -0.8% ) inks an agreement with British biotech Redx Pharma Plc to acquire its pan-RAF inhibitor program for the potential treatment of RAF- and RAS-mutant tumors. More news on: Jazz Pharmaceuticals plc, Healthcare stocks news, Read more ...

Jazz Pharmaceuticals (NASDAQ: JAZZ ) has signed a definitive agreement under to acquire Redx Pharma's (Redx) pan-RAF inhibitor program for the potential treatment of RAF and RAS mutant tumors. More news on: Jazz Pharmaceuticals plc, Healthcare stocks news, Read more ...